Wegovy Pens

Wegovy, also known by its generic name semaglutide, belongs to the class of medicines called GLP-1s. It is a licensed weight loss medication, approved in September 2023 by the MHRA as a prescription-only medication for weight management in adults with obesity or overweight individuals with at least one weight-related condition. A weekly injection of Wegovy, paired with a diet and exercise plan, can help reduce appetite and help you feel fuller for longer, leading to less calorie intake and weight loss.

Wegovy, UK’s branded version of semaglutide, is a prescription-only weight loss medication used to assist with weight loss and maintenance, in combination with a balanced diet and physical activity. Although its licensing covers individuals aged 12 years and over, at The Family Chemist we only provide this treatment for those over 18 years old. It can be prescribed to those with a BMI over 30 kg/ m² (obesity) or those with a BMI of 27 kg/ m² with a weight-related health condition. 

At The Family Chemist, we always consider your BMI and medical history to determine treatment eligibility and safety. 

Wegovy’s active ingredient, semaglutide, mimics the effects of the GLP-1 hormone, normally produced naturally in the gut to regulate appetite. Those on Wegovy will therefore consume less calories and have less cravings, leading to weight loss. 

Wegovy also helps control your eating habits. It can minimise ‘hedonic eating’, which is eating for pleasure, and improves executive function and the ability to make decisions about eating. It also helps regulate ‘homeostatic eating’, which is eating for hunger. These behavioural changes promote sustainable changes to control eating habits. 

Wegovy is a once-weekly injection, we advise injecting on the same day of the week. You will always start from the lowest dose of 0.25mg and increase gradually. Each Wegovy pen has 4 doses and will last for 4 weeks of treatment. 

When using a Wegovy pen, always check the following and read the information leaflet from your medication pack: 

1. Prepare: Store your new pens in the fridge. Before injecting always check the pen label to confirm it is the correct medication and inspect whether the liquid in the pen is clear and check the expiry date. Wash your hands and attach a new disposable needle to the pen. 
2. Check the flow: Follow the directions from the information leaflet to check the flow and prime the pen. You should see a drop of solution appear on the tip of the needle. This is usually only done when you first start a new pen.
3. Select your dose: Select the correct dose by turning the dose selector at the end of the pen.
4. Inject your dose: Your dose can be injected under the skin, in the upper arm, thighs or abdomen, hold the needle in and count slowly to 6 before removing it after the dial has reached 0. Do not inject into a muscle or vein. We would advise rotating the injection site to avoid inflammation and irritation.
5. Dispose: Cover the needle with the cap and dispose of it in a sharps container. Do not store the pen with the needle attached. 

*Wegovy 7.2mg is slightly different from the other doses as you will need to inject three doses of the 2.4mg. Read more about how to administer the dose here* 

We recommend watching the video: How to use the Wegovy pen.

The starting dose of Wegovy injection is 0.25mg. You can then gradually increase in a stepwise approach to the maximum weekly dose of 7.2mg. This gradual increase allows your body to adjust to the medication and ensures your safety.  

You should never inject more than advised and follow the stepwise instructions. If you experience side effects, you can remain on the same dose for another month to allow your body to adjust. If side effects continue, get in touch with our clinicians or your doctor.

• Weeks 1-4: 0.25mg once a week 

• Weeks 5-8: 0.5mg once a week 

• Weeks 9-12: 1mg once a week 

• Weeks 13-16: 1.7mg once a week 

• Weeks 17-20: 2.4mg once a week 

• Weeks 21 onwards: 7.2mg once a week 

The 7.2mg dose is taken by administering THREE doses of the 2.4mg pen to make up the 7.2mg dose. These three injections should be taken on the same day of the week, though it is important that you rotate the injection site to avoid bruising or skin irritation. 

A single 7.2mg pen is in development with NovoNordisk, and should be available later in the Summer/Autumn 2026.  

If you are considering moving up to the 7.2mg dose, you must have titrated gradually from the lowest strength of (0.25mg in line with legal regulations and pharmacist advice. This applies even if you have previously used another GLP-1 medication, such as Mounjaro or Nevolat). 

As with each increase in dose, side effects may occur or become more noticeable. If side effects become difficult to manage, you should contact your healthcare provider for advice. They may advise that you reduce the dose to better manage your health. Do not make any dose changes unless advised by a clinical team. 

You will notice reduced appetite and feeling fuller quicker when eating food. A 72-week study on Wegovy’s use discovered that individuals using the 7.2mg dose for maintenance, achieved (on average) a 21% body weight reduction compared to the start of treatment and compared with a 2.4% body weight loss when individuals were given placebo. The STEP UP phase 3b study also found that 33.2% of participants lost ~25% of their initial body weight on Wegovy injections.   

To achieve the best results, it’s important to follow a balanced diet and exercise plan. You can find out more about our additional support through our coaching service.

Wegovy trials also showed that patients also noticed an improvement in their blood pressure, blood cholesterol, glycaemic control and overall cardiovascular health. MHRA has approved Wegovy as a treatment to reduce cardiovascular risk for obese or overweight individuals. Trials showed that Wegovy can reduce the risk of major cardiovascular events (such as stroke or heart attack) by 20%.  

In prior, more in depth clinical trials using the hight of the 2.4mg pen, they found: 

• 33.9% of Semaglutide patients lost over 20% of their body weight. 

• 53.5% of Semaglutide patients lost more than 15% of their body weight. 

• 73% of Semaglutide patients lost more than 10% of body weight. 

• 84.8% of Semaglutide patients lost more than 5% of body weight. 

Whilst Wegovy is a fully licensed treatment option, it may not be suitable for everyone. 

• Allergies: If you’re sensitive or allergic to semaglutide or any of Wegovy’s ingredients, you should avoid using it. 

• Pregnancy and breastfeeding: Wegovy, and all GLP-1s are not safe in pregnancy or breastfeeding. You should use effective contraception during treatment and avoid conceiving whilst on Wegovy and for at least 8 weeks after your last dose. Its effects on the unborn baby are unknown and we therefore advise that you stop treatment immediately if you find out you are pregnant. 

• Type 1 Diabetes or Diabetic Retinopathy: Wegovy is not an insulin substitute but may impact glucose control, this can negatively affect diabetes control and worsen eye symptoms.  

• History of Thyroid Cancer: If you have a personal, or family history of medullary thyroid carcinoma, you should avoid using Wegovy. Trials suggested it may increase risk of developing thyroid tumors. 

• Those under 18 or over 75 years of age. 

• Those suffering from liver or kidney disease, diabetic retinopathy, history of pancreatitis, severe stomach or gut problems (including gastroparesis) or severe inflammatory bowel disease. 

If you’re unsure whether Wegovy is right for you, please consult a healthcare professional. Always disclose all existing medications and conditions when completing your consultation. 

Wegovy can cause side effects like all medicines, although not everybody gets them. The following side effects reported are: 

Very common: may affect more than 1 in 10 people 

• Feeling sick (nausea), being sick (vomiting), diarrhoea, constipation, headache, abdominal pain and fatigue usually go away after a few days or weeks. 

While undergoing Wegovy treatment, you may experience nausea, vomiting, or diarrhoea. These symptoms can lead to dehydration, so drinking plenty of fluids is crucial to prevent this. Staying hydrated is particularly vital if you have pre-existing kidney issues. 

Common: may affect up to 1 in 10 people 

• feeling dizzy 

• upset stomach or indigestion 

• burping 

• gas (flatulence) 

• bloating of the stomach 

• inflamed stomach (‘gastritis’) – the signs include stomach ache, feeling sick (nausea) or being sick (vomiting) 

• reflux or heartburn – also called ‘gastro-oesophageal reflux disease’ 

• gallstones 

• hair loss 

• injection site reactions 

• low blood sugar (hypoglycaemia) in patients with diabetes. 

Serious Side Effects of Wegovy. 

If you experience any side effects below, stop using Wegovy and see your doctor immediately. 

• Pancreatitis: In rare cases, Wegovy may increase the risk of pancreatitis, which is pancreas inflammation. Symptoms may include severe abdominal pain that can radiate to the back, nausea, and vomiting. 

• Gallbladder Problems: Some individuals using Wegovy may experience gallbladder-related issues, such as gallstones. Symptoms may include abdominal pain, particularly in the upper right side, and discomfort after eating fatty foods. 

• Low Blood Sugar (Hypoglycaemia): While people do not primarily use Wegovy to treat diabetes., it can lower blood sugar levels. If you have diabetes or take other medications that reduce blood sugar, there may be an increased risk of hypoglycaemia. The warning signs of low blood sugar may come on suddenly. They can include cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or hungry, vision changes, feeling sleepy or weak, nervousness, anxiety or confusion, difficulty concentrating or shaking. Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. 

• Diabetic Retinopathy: Individuals with diabetic retinopathy undergoing treatment with insulin and semaglutide may experience a higher likelihood of developing complications related to diabetic retinopathy. The prompt enhancement in glucose management has been linked to a transient deterioration of diabetic retinopathy, though other contributing factors could exist. Those with diabetic retinopathy utilising semaglutide should receive close observation and care. 

• Increase heart rate 

• Allergic reaction 

The list above does not include all possible side effects, therefore it is vital that if you experience any serious side effects whilst using this medication to consult a healthcare professional and if you experience side effects not listed above, complete a MHRA Yellow Card report. 

Be sure to read through the patient information leaflet before taking any new medication to familiarise yourself with the possible side effects, cautions, and contraindications. You should only take Wegovy once you have understood all the warnings and precautions. If you are concerned discuss this with your doctor or a The Family Chemist clinician. 

If you miss a dose of Wegovy, follow these guidelines: 

• If you remember within 5 days or less of your scheduled injection day, inject as soon as you remember and continue with your usual schedule the next day. 

• If you remember after 5 days, skip the missed dose. You can continue with your treatment from your next injection day.  

• Never double-dose. If you miss multiple doses, speak with your care provider as you may need to start on a lower dose to minimise risk of serious side effects.

There are a range of alternative medications to Wegovy that are licensed for use in the UK. These include weight loss injections, and weight loss tablets, which are available through The Family Chemist. All treatment options are provided alongside dietary and lifestyle changes. 

Nevolat, Mounjaro and Wegovy all work in a similar way by mimicking GLP hormones. However, they differ in active ingredients, effectiveness, and method of administration.

If medicated options are not suitable for you, there are some alternative options to consider: 

1. Behavioural Therapy: Weight management often involves changes in diet and exercise habits. Behavioural therapy, either individually or in group settings, can provide valuable strategies and support for making lifestyle changes. 
2. Dietary Counseling: Working with a registered dietitian or nutritionist can help you develop a personalized meal plan that aligns with your weight loss goals and dietary preferences. 
3. Exercise Programs: Regular physical activity is essential for weight management. Consider engaging in an exercise program or working with a personal trainer to establish a fitness routine. 
4. Lifestyle Changes: Small but sustainable changes in your daily habits, such as portion control, mindful eating, and adequate sleep, can contribute significantly to weight loss. 
5. Surgical Options: In cases of severe obesity, surgical procedures like gastric bypass, gastric sleeve, or lap band surgery may be considered a last resort.  

• Keep Wegovy out of reach of children 

• Do not use after the expiry date printed on the pen and box. The expiry date refers to the last day of that month 

• Store unopened pens in the fridge (2°C to 8°C). Do not freeze. 

• Once in use, you can store the pen in a fridge or at room temperature (below 30°C) for up to 30 days. 

• Discard pens 6 weeks after opening 

• Always store the pen with the cap on, and dispose of used needles appropriately. 

• Do not discard medication in household waste. Ask your local pharmacy or doctor’s surgery to dispose of any pharmaceutical waste. 

No. It can be dangerous to take multiple weight loss medications at the same time. We cannot provide Wegovy if you are already on other treatments. You can switch between treatments, but you must first consult your doctor and may be advised to have a sufficient treatment gap for your safety.

Wegovy and Ozempic both contain the same active ingredient, Semaglutide. Wegovy holds a license for weight management, while Ozempic holds a license for type 2 diabetes treatment. The Family Chemist advises against using Ozempic for weight loss as it reduces availability for type 2 diabetes patients and its use for weight loss is unlicensed.

Wegovy and Rybelsus both contain the same active ingredient, Semaglutide. Wegovy holds a license for weight management, and is injected subcutaneously, but Rybelsus is approved for type 2 diabetes treatment and is available in an oral tablet form. The Family Chemist advises against using Rybelsus for weight loss as it reduces availability for type 2 diabetes patients and its use for weight loss is unlicensed.

Wegovy is the brand name for semaglutide and the only injectable semaglutide licensed in the UK for weight loss.

Yes, you may be able to get Wegovy through the NHS but the prescribing criteria differ from private services. You may be able to get Wegovy through: 

1. Referral to a tier 3 weight management service. You’ll need to meet the criteria and there’ll be a waiting list. How long it takes for your referral depends on your area and waiting times vary from a few months to a few years. 
2. Some GPs and pharmacists are receiving training to prescribe weight loss injections, but this is still in testing by the NHS so may not be available in your area. Ask your GP or community pharmacy for more information. 

It’s essential to exercise caution and consult with your healthcare provider regarding alcohol consumption while taking Wegovy or any medication. Here are some important considerations: 

1. Potential Interaction: While Wegovy primarily works on appetite control and blood sugar regulation, alcohol can affect your body in various ways, including blood sugar levels. Combining Wegovy with alcohol might have unpredictable effects on your body, so it’s essential to be cautious.
2. Personal Tolerance: People’s tolerance for alcohol can vary widely. Wegovy can affect how your body processes substances, so you may find that your response to alcohol is different while taking this medication. 
3. Side Effects: Both Wegovy and alcohol can potentially cause nausea. Combining the two may increase the likelihood of experiencing nausea or gastrointestinal discomfort. 
4. Weight Loss Goals: If you are using Wegovy to support your weight loss goals, it’s important to note that alcoholic beverages often contain extra calories and can hinder your progress if consumed excessively. 
5. Safety Concerns: Alcohol can impair your judgment and coordination. Avoiding situations where impaired judgment could lead to accidents or risky behaviours is essential. 

No. The potential effects of Wegovy on an unborn baby is not fully understood at this point. We would advise you to use effective contraception while on Wegovy injections, and for at least 8 weeks after stopping it before trying to conceive. 

It is also not advised to breastfeed while on Wegovy as it is unclear whether the medication will pass through the breastmilk.

Wegovy, or semaglutide, typically has a relatively long half-life, which means it remains active in your system for an extended period. Wegovy has a half-life of approximately one week, which means your body eliminates half of the medication in about one week. 

Because of this long half-life, Wegovy can continue to affect your body for several weeks after you stop taking it. However, the precise duration can vary from person to person based on factors like metabolism and individual differences.

Each Wegovy box contains ONE Wegovy FlexTouch pen, 4 Novofine Plus needles and a leaflet. It does not come with a sharps bin or alcohol swabs, but these are needed when administering each dose. These can all be purchased separately from ourselves or any community pharmacy.

Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021) The New England Journal of Medicine [accessed 10th February 2026]  

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (2022) Nature Medicine] [accessed 10th February 2026] 

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4) (2021) JAMA] [accessed 10th February 2026] 

Semaglutide 2.4 mg once weekly in adults with overweight or obesity, and type 2 diabetes (STEP 2 Trial) (2021) The Lancet] [accessed 10th February 2026] 

Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg solution for injection in pre-filled pen (2024) Electronic Medicines Compendium (EMC): Patient Information Leaflet] [accessed 10th February 2026] 

Wegovy (semaglutide) Summary of Product Characteristics (2024) Electronic Medicines Compendium (EMC)] [accessed 10th February 2026] 

MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults (2024) GOV.UK] [accessed 10th February 2026] 

Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity (SELECT Trial) (2023) PubMed / SELECT CVOT Overview [accessed 10th February 2026]  

A Research Study to Look at How Well Semaglutide Helps People Lose Weight (STEP UP – Phase 3b) (2024) ClinicalTrials.gov] [accessed 10th February 2026] 

Wegovy® (semaglutide) Injection: Your Complete Guide to Wegovy Pen (2026) Novo Nordisk] [accessed 10th February 2026] 

Semaglutide for managing overweight and obesity (2023) NICE] [accessed 10th February 2026]